Astria Therapeutics, Inc. (ATXS) has disclosed a new risk, in the Cyber Security category.
Astria Therapeutics, Inc. faces significant business risks stemming from the integration of artificial intelligence into its operations and those of its vendors. The company’s reliance on AI, compounded by a volatile regulatory landscape, could lead to reputational damage, legal liabilities, or other detrimental effects on its business activities. The undisclosed use of generative AI by vendors, along with potential breaches and insufficient privacy and data protection standards, poses a threat to Astria’s intellectual property and confidential data. Moreover, sophisticated cybercriminals utilizing AI for illicit activities amplify the risk of theft and misuse of sensitive information, potentially harming Astria’s reputation and operational integrity.
Overall, Wall Street has a Strong Buy consensus rating on ATXS stock based on 6 Buys.
To learn more about Astria Therapeutics, Inc.’s risk factors, click here.
